Traws Pharma (TRAW) AI Stock Analysis

• Market Cap: $8.24M
• Dividend Yield: N/A
• Average Volume (3M): 2.31M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: N/A
• EPS Growth: -404.67%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 2.17
• Shares Outstanding: 5,564,315
• 10 Day Avg. Volume: 6,583,206
• 30 Day Avg. Volume: 2,310,256
• PEG Ratio: 0.02
• Price to Book (P/B): -1.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.32
• Enterprise Value/Market Cap: -1.43
• Enterprise Value/Revenue: -13.00
• Enterprise Value/Gross Profit: -53.25
• Enterprise Value/Ebitda: 0.12
• 1Y Price Target: $6.00
• Price Target Upside: 263.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 28 Underperform
• Price Target: ―

Traws Pharma's overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.

Traws Pharma Business Overview & Revenue Model

Company Description

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

How the Company Makes Money

Traws Pharma generates revenue primarily through the sale of its pharmaceutical products and therapies that have gained regulatory approval. The company also engages in licensing agreements, where it grants other pharmaceutical firms access to its proprietary technologies and compounds in exchange for upfront payments, milestone fees, and royalties on sales. Additionally, Traws Pharma may receive funding from research grants and collaborations with academic institutions or other industry players. Strategic partnerships with larger pharmaceutical companies also contribute to its earnings, facilitating the co-development and co-promotion of new therapies.

Traws Pharma Financial Statement Overview

Summary

Traws Pharma faces significant financial challenges with persistent losses, negative equity, and reliance on external financing. The lack of revenue growth and profitability highlights the need for strategic changes to improve financial health.

Income Statement

Traws Pharma's income statement reveals persistent losses over the years, with no revenue growth and negative EBIT and EBITDA margins. The net profit margin is consistently negative, indicating ongoing profitability challenges.

Balance Sheet

The balance sheet shows negative stockholders' equity, indicating financial distress. The equity ratio is negative due to liabilities exceeding assets, and there is no debt, which mitigates risk but also highlights the lack of financial leverage.

Cash Flow

Cash flow analysis indicates negative free cash flow and operating cash flow, with an inability to cover operating expenses. The company relies heavily on financing activities to sustain operations, which is unsustainable in the long term.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
227.00K	226.00K	226.00K	226.00K	226.00K	231.00K
	Gross Profit
221.00K	214.00K	210.00K	212.00K	212.00K	231.00K
	EBIT
-24.90M	-142.37M	-20.30M	-19.63M	-16.50M	-24.99M
	EBITDA
-24.89M	-24.90M	-20.28M	-19.61M	-16.48M	-24.98M
	Net Income Common Stockholders
-140.05M	-166.52M	-18.95M	-18.96M	-16.16M	-25.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
15.94M	21.34M	20.82M	38.76M	55.07M	19.02M
	Total Assets
19.06M	24.96M	22.68M	39.37M	55.48M	19.99M
	Total Debt
0.00	0.00	0.00	0.00	0.00	0.00
	Net Debt
-15.94M	-21.34M	-20.82M	-38.76M	-55.07M	-19.02M
	Total Liabilities
13.06M	56.59M	12.01M	11.06M	9.36M	13.81M
	Stockholders Equity
6.00M	-31.63M	10.67M	28.31M	46.12M	6.17M
Cash Flow		Free Cash Flow
-30.80M	-29.79M	-17.95M	-16.29M	-19.49M	-23.09M
	Operating Cash Flow
-30.80M	-29.79M	-17.93M	-16.29M	-19.49M	-23.07M
	Investing Cash Flow
-3.65M	-3.65M	-14.00K	0.00	0.00	-15.00K
	Financing Cash Flow
33.99M	33.98M	0.00	0.00	55.56M	19.36M

Traws Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.65
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRAW, the sentiment is Positive. The current price of 1.65 is above the 20-day moving average (MA) of 1.38, above the 50-day MA of 1.64, and below the 200-day MA of 4.91, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 54.14 is Neutral, neither overbought nor oversold. The STOCH value of 30.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRAW.

Traws Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.24B	3.27	-45.39%	2.80%	16.77%	-0.07%
ADXN	45 Neutral	$12.78M	1.11	-92.60%	―	-70.05%	―
IBIO	42 Neutral	$15.31M	―	-90.83%	―	650.00%	89.72%
AFMDQ	42 Neutral	$1.06M	―		―	-95.23%	-325.89%
PSTV	41 Neutral	$10.44M	―	249.03%	―	-14.43%	16.04%
RLYB	35 Underperform	$14.12M	―	-67.28%	―	―	27.35%
TRAW	28 Underperform	$8.24M	―	-576.08%	―	―	-404.67%

Traws Pharma Corporate Events

Traws Pharma Appoints New Chairman Amid Leadership Changes

Traws Pharma, Inc. announced the appointment of Iain Dukes as the Interim Chief Executive Officer effective March 31, 2025, with an employment agreement effective April 1, 2025. This agreement outlines a one-year term, renewable annually, and includes a base salary of $610,000 with eligibility for an annual bonus. The agreement also specifies severance terms and benefits in case of termination. Additionally, on April 15, 2025, Dr. Dukes stepped down as Chairman of the Board, with Jack Stover appointed as the new Chairman, while Dr. Dukes remains a board member.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.

Traws Pharma’s overall stock score reflects significant financial challenges, including persistent losses and reliance on external financing. The technical analysis indicates a bearish trend, and the valuation shows a negative P/E ratio, further emphasizing the company’s financial difficulties. Despite some positive corporate events, such as securing financing and progress in investigational programs, these are insufficient to offset the broader financial struggles.

To see Spark’s full report on TRAW stock, click here.

Traws Pharma Reports 2024 Financial Results and CEO Change

On March 31, 2025, Traws Pharma announced its financial results for the year ending December 31, 2024, and highlighted significant progress in its investigational programs. The company reported positive data for its lead product candidate, tivoxavir marboxil, in treating bird flu, and ongoing FDA interactions for potential accelerated approval. Additionally, Traws Pharma completed a successful financing round, securing $20 million to support operations into Q1 2026. The company also announced the retirement of its CEO, Werner Cautreels, with Iain D. Dukes stepping in as Interim CEO.

Traws Pharma Announces CEO Transition and Investor Update

On March 28, 2025, Traws Pharma announced the retirement of CEO Werner Cautreels, effective March 31, 2025, with Iain D. Dukes stepping in as Interim CEO. Dr. Cautreels will remain on the Board and transition to a consulting role, while Dr. Dukes, with extensive leadership experience, will continue as Chairman. The company is advancing its antiviral programs for bird flu and COVID-19, with an investor update scheduled for March 31, 2025.

Traws Pharma Regains Nasdaq Compliance with $20M Financing

Traws Pharma announced on February 28, 2025, that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement, ensuring continued listing on the Nasdaq Capital Market. This follows a successful hearing and a $20 million financing, positioning Traws to advance its antiviral programs, particularly for bird flu and influenza, while being subject to a one-year monitoring period to maintain compliance.